Tag: Carag

Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework

Coronary/Structural Heart Regulatory by 0 comments

The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach BAAR, Switzerland, July 1, 2020 /PRNewswire/ — CARAG AG, a privately-held Swiss medical device development company, today announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for its Carag Bioresorbable […]

Continue Reading →

Innovative implant for occlusion of heart defects

Coronary/Structural Heart by 0 comments

CARAG Completes CE Marking for its Breakthrough Carag Bioresorbable Septal Occluder (CBSO) Innovative bioresorbable implant of Carag removes risks associated with conventional metal frameworks and expands treatment options for patients with heart defects. CARAG AG, a privately held medical device development company, today announced that it has completed CE (Conformité […]

Continue Reading →